Press Conference 1: Saturday, 8 October 2016

Moderator: Evandro De Azambuja

  • LBA1_PR: First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Monaleesa 2Gabriel Hortobagyi            Published in the New England Journal of Medicine


  • LBA2_PR: Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Alexander Eggermont Published in the New England Journal of Medicine 
  • LBA3_PR: A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Mansoor Raza Mirza Published in the New England Journal of Medicine